Welcome to the Duke Comprehensive Cancer Center

Physician-researchers at Duke University Medical Center led by P. Kelly Marcom, MD, opened a clinical trial on May 1 to test genomic tools that will enable physicians to predict which chemotherapies will be most effective in early-stage breast cancer patients. “There are a number of possible chemotherapies that can be administered by a physician,” explains Marcom. “Determining which patient will respond positively to which treatment can be extremely difficult.” Duke investigators are pioneers in the design of the genomic predictors that will be used in the study to determine which of the chemotherapies already available will be most beneficial to each individual patient based on the genomic profile of the tumor. The plan is to enroll a total of 270 patients; 100 will be patients treated at the Duke Comprehensive Cancer Center. The remainder of the patients will be identified by working with oncologists at Duke Raleigh Hospital, Durham Regional Hospital, and at affiliate hospitals across the Southeast.  
 
 
For more information about the study, visit genomestohealth.org

Pictured: P. Kelly, Marcom, MD